Eton Pharmaceuticals’ NDA for Khindivi receives US FDA nod for oral solution formulation: Deer Park, Illinois Friday, May 30, 2025, 13:00 Hrs [IST] Eton Pharmaceuticals, Inc, an ...

The Food and Drug Administration (FDA) has approved Khindivi ™ (hydrocortisone) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.

KHINDIVI is the only FDA-approved oral liquid formulation of hydrocortisone, specifically designed for children five years and older who require replacement therapy for adrenocortical insufficiency.

Eton Pharmaceuticals (ETON) stock gains as the FDA approved Khindivi its oral hydrocortisone solution for children with adrenocortical insufficiency. Read more here.

Khindivi is the sole FDA-approved hydrocortisone oral solution and is available in a 1mg/ml concentration. This formulation ...

KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocort ...

Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) saw a 3.3% boost in premarket trading after the company announced U.S. Food ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received FDA approval for KHINDIVI, the first and only hydrocortisone oral ...

Eton Pharmaceuticals, Inc (“Eton” or“the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S.

KHINDIVI is the first and only FDA-approved hydrocortisone oral solution • Commercial launch expected the week of June 2 nd • ...

This work aimed to develop an optimized lipid polymer hybrid nanoparticle and assess the skin delivery effectiveness of hydrocortisone (9.872 ± 0.361 × 10 –3 cm 2 /h) of a drug through the skin from ...

Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills FRIDAY, May 16, 2025 (HealthDay News) — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to ...